Special Drug Use Surveillance of EFIENT Tablet - Prasugrel For Japanese patients with ischemic heart disease in long-term use clinical practice -

Special Drug Use Surveillance of EFIENT Tablet - Prasugrel For Japanese patients with ischemic heart disease in long-term use clinical practice - - PRASFIT-Practice II

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018003

Enrollment

4000

Registered

2015-06-23

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with any of the ischemic heart diseases specified below that require PCI: Acute coronary syndrome (unstable angina pectoris, ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction), stable angina pectoris, old myocardial infarction.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with any of the ischemic heart diseases specified below that require PCI : Acute coronary syndrome (unstable angina pectoris, ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction), stable angina pectoris, old myocardial infarction.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Safety 1) Frequency of adverse drug reactions 2) Frequency of severe adverse events 3) Frequency of bleeding events Efficacy - Frequency of cardiovascular events Special population - Safety and efficacy in patients with hepatic disease, renal disease, and elderly	—

Countries

Japan

Contacts

Public ContactHIROHIDE OUCHI

Daiichi Sankyo Co., Ltd. Post Marketing Study Department

ouchi.hirohide.bm@daiichisankyo.co.jp+81-3-6225-1044

Outcome results